Skip to main content

Home/ Nutrition/ Group items tagged chd

Rss Feed Group items tagged

Matti Narkia

Meta-analysis of prospective cohort studies evaluating the association of saturated fat... - 2 views

    Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.
    Siri-Tarino PW, Sun Q, Hu FB, Krauss RM.
    Am J Clin Nutr. 2010 Jan 13. [Epub ahead of print]
    PMID: 20071648

    Conclusions: A meta-analysis of prospective epidemiologic studies showed that there is no significant evidence for concluding that dietary saturated fat is associated with an increased risk of CHD or CVD. More data are needed to elucidate whether CVD risks are likely to be influenced by the specific nutrients used to replace saturated fat.
Matti Narkia

Vitamin D and Disease Incidence Prevention | Free The Animal - 0 views

    "For what reason I don't know, but this January 2009 editorial by William Faloon of the Life Extension Foundation is making the rounds. Perhaps it just came available on the web.

    It's a good read, particularly in light of the billions and trillions of dollars the thieves & thugs in DC are about to flush down the crapper on your behalf. Some notable excerpts.

    A large number of new vitamin D studies have appeared in the scientific literature since I wrote my plea to the federal government. These studies don't just confirm what we knew 16 months ago-they show that optimizing vitamin D intake will save even more lives than what we projected.

    For instance, a study published in June 2008 showed that men with low vitamin D levels suffer 2.42 times more heart attacks. Now look what this means in actual body counts.

    Each year, about 157,000 Americans die from coronary artery disease-related heart attacks. Based on this most recent study, if every American optimized their vitamin D status, the number of deaths prevented from this kind of heart attack would be 92,500.

    To put the number of lives saved in context, tens of millions of dollars are being spent to advertise that Lipitor® reduces heart attacks by 37%. This is certainly a decent number, but not when compared with how many lives could be saved by vitamin D. According to the latest study, men with the higher vitamin D levels had a 142% reduction in heart attacks."
Matti Narkia

Hyperlipid: Cholesterol within nations studies - 0 views

    "These are the slides from the within-countries discussion on cholesterol and heart disease. I've allowed the sarcasm back in, which was strictly limited when the slides were originally presented. OK, there is a correlation. In fact, if you are a bloke, having a cholesterol above that certain magic number on the graph is clearly catastrophic and boy, are you in trouble. No statins to save your life in those days!"
Matti Narkia

Diet and Coronary Thrombosis.,Hypothesis and Fact - Yudkin J - Lancet 1957 - Image001.... - 0 views

    Diet and Coronary Thrombosis., Hypothesis and Fact
    Yudkin J.
    The Lancet 1957.

    (Figure 9 only)
Matti Narkia

Nutritional diseases - - 0 views

    "What Are Nutritional Diseases?

    In their book, The Modern Nutritional Diseases, Fred and Alice Ottoboni, retired Public Health Service scientists, list the following.
    * Obesity
    * Diabetes II
    * Cardiovascular Diseases
    * Stroke.
    * Cancer.

    Modern nutritional diseases are just that. They haven't always been the ugly part of our life. They were introduced when people had to get their food from grocery stores, when people traded their whole foods from the family farm for those manufactured by the food processing industry. "
Matti Narkia

Seven Countries Study - - 0 views

    "Coronary Heart Disease Mortality and Blood Cholesterol

    In the Seven Countries study, there were great differences in coronary heart disease (CHD) mortality at similar blood cholesterol levels.

    In this study Dr. Keys pointed to a correlation between deaths from coronary heart disease and serum cholesterol in 15 populations in seven countries.

    Dr Ravnskov plotted his original data which was not available in the research summaries. Particularly interesting were differences between two localities within the same country or nearby islands in each of 4 of the seven countries.

    West Finland had about 45 CHD (coronary heart disease) deaths at a median cholesterol level of 250 mg/dl. However North Karelia, also in Finland, had over 200 CHD deaths at about 260 mg/dl.

    The island of Crete had only 20 CHD deaths at cholesterol levels of about 200. The nearby island of Corfu had about 85 CHD deaths at a cholesterol level of about 190 mg/dl."
Matti Narkia

Hyperlipid: Professor John Yudkin and Dr Ancel Keys - 1 views

    "Here's a page or so (p163-4) from John Yudkin's book "Pure White and Deadly", 1972 edition. Yudkin begins the chapter with an apology for talking about such uncomfortable disagreements in public. But he liked the truth.

    This quote covers opinion from Prof John Yudkin and Dr Meyer Friedman. You can hear their dislike of Keys. Keys was the architect of what has become the current world obesity epidemic and never one to let the truth get in the way of a good idea, as with his six nations "fat causes heart disease" study. Unfortunately Meyer's list of those easily misled did not include gullible politicians who set food policy. Keys was a very successful politico, with intense conviction of his own correctness. Fine if he had been right, which he wasn't."
Matti Narkia

Calcium:Magnesium Ratio in Local Groundwater and Incidence of Acute Myocardial Infarcti... - 0 views

    Calcium:magnesium ratio in local groundwater and incidence of acute myocardial infarction among males in rural Finland.
    Kousa A, Havulinna AS, Moltchanova E, Taskinen O, Nikkarinen M, Eriksson J, Karvonen M.
    Environ Health Perspect. 2006 May;114(5):730-4.
    PMID: 16675428

    Results of this study with specific Bayesian statistical analysis support earlier findings of a protective role of Mg and low Ca:Mg ratio against coronary heart disease but do not support the earlier hypothesis of a protective role of Ca
Matti Narkia

Unexpected Perks of Coffee Consumption - The Early Show - CBS News - 0 views

    "(CBS) Your daily cup of java may deliver some unexpected health benefits. Studies have shown it may lower your risk for Type II diabetes and certain types of cancer (colon, mouth and throat), and protect against heart disease and cavities.

    Dr. Alanna Levine, a primary care physician, said on "The Early Show" researchers aren't sure exactly why coffee has these benefits, but speculated that perhaps the coffee has antioxidant properties. "
Matti Narkia

Whole Health Source: Eicosanoids and Ischemic Heart Disease, Part II - 0 views

    "Wednesday, May 27, 2009
    Eicosanoids and Ischemic Heart Disease, Part II
    Here's where it gets more complicated and more interesting. The ratio of omega-6 to omega-3 matters, but so does the total amount of each. This is a graph from a 1992 paper by Dr. Lands:

    In sum, this suggests that the single best way to avoid a heart attack is to reduce omega-6 consumption and ensure an adequate source of omega-3. The lower the omega-6, the less the omega-3 matters. This is a nice theory, but where's the direct evidence? In the next post, I'll discuss the controlled trial that proved this concept once and for all: the Lyon diet-heart trial.
Matti Narkia

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortal... - 0 views

    C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
    The Lancet, Early Online Publication, 22 December 2009

    CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size. The relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease depend considerably on conventional risk factors and other markers of inflammation.
Matti Narkia

Largest-ever meta-analysis finds CRP is unlikely to be causal for CVD - - 0 views

    "Largest-ever meta-analysis finds CRP is unlikely to be causal for CVD
    December 21, 2009 | Lisa Nainggolan

    Cambridge, UK - In the largest and most comprehensive meta-analysis to date looking at C-reactive-protein (CRP) levels and risk of coronary heart disease (CHD) and stroke, British researchers conclude that CRP is unlikely to be a causal factor for cardiovascular disease [1].

    Although CRP concentration was linearly associated with CHD, stroke, and vascular mortality, as well as nonvascular mortality, statistical adjustment for conventional cardiovascular risk factors "resulted in considerable weakening of associations," note the scientists of the Cambridge-based Emerging Risk Factors Collaboration (ERFC), who report their findings online December 21, 2009 in the Lancet.

    In an editorial accompanying the paper [2], Drs S Matthijs Boekholdt and John JP Kastelein (Academic Medical Center, Amsterdam, the Netherlands) say the UK authors "are to be commended for this impressive data set." Although the findings "add weight to the evidence of noncausality" for a role of CRP in the development of cardiovascular disease, "the debate can be resolved only by randomized trials with agents that specifically target CRP, and such compounds are currently under development," say the Dutch doctors.

    Commenting on the new meta-analysis for heartwire, Dr Paul Ridker (Brigham and Women's Hospital, Boston, MA), a long-time advocate of CRP and the lead investigator of the JUPITER trial, said: "Whether or not CRP is 'causal' for heart disease is neither the crucial issue at hand nor relevant for public health. What is crucial is getting international agreement that CRP identifies higher-risk individuals who would not otherwise qualify for a life-saving therapy, and then showing that such individuals clearly benefit from treatment. The new meta-analysis demonstrates the former, and JUPITER demonstrates the latter." "
Matti Narkia

Quality of HDL differs in diabetics but improves with niacin therapy - - 1 views

    "Quality of HDL differs in diabetics but improves with niacin therapy
    December 22, 2009 | Michael O'Riordan

    Hannover, Germany - A small study published this week hints that the effects of HDL cholesterol differ in healthy patients from those with diabetes mellitus [1]. HDL cholesterol in individuals with diabetes has impaired endothelial protective functions compared with the HDL from healthy subjects, although treatment with extended-release niacin can improve these endothelial protective effects, according to researchers.

    Publishing their findings online December 21, 2009 in Circulation, lead investigator Dr Sajoscha Sorrentino (Hannover Medical School, Germany) and colleagues write that because recent HDL-raising intervention studies have yielded mixed results, "circulating HDL-cholesterol levels alone likely do not represent an adequate measure of therapeutic efficacy, and indexes of HDL functionality are urgently needed for assessment of the potential of HDL-targeted therapies to exert vasoprotective effects."

    Speaking with heartwire, senior investigator Dr Ulf Landmesser (University of Zürich, Switzerland), said the results have implications for clinical research.

    "We have to understand that we can't look only at the HDL levels in the plasma, but we need to look at the quality," he said. "The quality of the HDL is not the same in different patients. This is very important for targeting HDL as a treatment. Second, niacin therapy is a promising way not only to raise HDL but also to improve the quality; it is a good treatment option, especially if the larger outcomes data are positive.""
Matti Narkia

Vitamin B Niacin Offers No Additional Benefit To Statin Therapy In Seniors Already Diag... - 0 views

    "The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.

    In tests on 145 Baltimore-area men and women with existing atherosclerosis, all over age 65, researchers found that after 18 months of drug therapy, reductions in arterial wall thickness were measurably no different between the half who took dual niacin-statin therapy and the rest who remained on statin therapy alone. "
Matti Narkia

NEJM -- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reacti... - 0 views

    Conclusions In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. \n\nRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.\nRidker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.\nN Engl J Med. 2008 Nov 20;359(21):2195-207. Epub 2008 Nov 9.\nPMID: 18997196
Matti Narkia

NEJM -- Expanding the Orbit of Primary Prevention -- Moving beyond JUPITER - 0 views

    Expanding the orbit of primary prevention--moving beyond JUPITER.
    Hlatky MA.
    N Engl J Med. 2008 Nov 20;359(21):2280-2. Epub 2008 Nov 9.
    PMID: 18997195
Matti Narkia

Statins in the Water? Not So Fast - Well Blog - - 0 views

    Last week, Harvard researchers reported how healthy 50-year-old men and 60-year-old women could benefit from taking a statin even if they didn't have high cholesterol. The people they studied had high levels of C-reactive protein, or CRP, which is a marker for inflammation. The study showed that risk for major heart problems was cut by about 50 percent among the statin users.\n\nBut like many industry-sponsored drug studies, the results focused on something called "relative risk," which compares differences between study groups. Relative risk has the effect of exaggerating a drug's benefits. What does a 50 percent reduction in heart risk mean? It means that just one out of 120 statin users was helped by the drug.
Matti Narkia

Well - A Call for Caution in the Rush to Statins - - 0 views

    Judging by recent headlines, you might think so. Last week heart researchers reported that millions of healthy people could benefit from taking statins even if they don't have high cholesterol.\n\nAlthough many doctors hailed the study as a major breakthrough, a closer look at the research suggests that statins (like Crestor, from AstraZeneca, and Lipitor, from Pfizer) are far from magic pills. While they clearly save lives in people with a previous heart attack or other serious heart problems, for an otherwise healthy person the potential benefit remains small.
Matti Narkia

Cholesterol-Fighting Drugs Show Wider Benefit - New York Times - 0 views

    CHART: Statins Reduce Risks: A study of 18,000 people with high levels of C-reactive protein, or CRP, found that the risk of a heart attack or stroke was cut in half among those who took a statin. The study was stopped after two years, but some participants were tracked for up to five years. (Sources: Dr. Paul M. Ridker; New England Journal of Medicine) (pg.A21)
    A large new study suggests that millions more people could benefit from taking the cholesterol-lowering drugs known as statins, even if they have low cholesterol, because the drugs can significantly lower their risk of heart attacks, strokes and death.

    The study, involving nearly 18,000 people worldwide, tested statin treatment in men 50 and older and in women 60 and older who did not have high cholesterol or histories of heart disease. What they did have was high levels of a protein called high-sensitivity C-reactive protein, or CRP, which indicates inflammation in the body.
Matti Narkia

JUPITER: Primary-prevention statin therapy in women cuts cardiovascular risk in half - ... - 1 views

    "November 25, 2009 | Michael O'Riordan

    Orlando, FL - Treating healthy women with low LDL cholesterol but elevated high-sensitivity C-reactive protein (hsCRP) levels with rosuvastatin (Crestor, AstraZeneca) cuts their risk of cardiovascular events in half, according to a new analysis of Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).

    The reduction in risk is consistent with the reduction observed in the overall trial, and with the 42% benefit observed in men.
1 - 20 of 223 Next › Last »
Showing 20 items per page